Guggenheim Has Lowered Expectations for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its price objective reduced by equities researchers at Guggenheim from $120.00 to $100.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would suggest a potential upside of 26.68% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Zacks Research raised shares of Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. BTIG Research reduced their price objective on Billiontoone from $160.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Piper Sandler reiterated an “overweight” rating on shares of Billiontoone in a report on Wednesday, December 10th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, William Blair initiated coverage on Billiontoone in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $126.71.

Billiontoone Stock Performance

Shares of BLLN opened at $78.94 on Monday. The stock’s 50-day simple moving average is $79.59. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32. Billiontoone has a 1 year low of $61.96 and a 1 year high of $138.70. The firm has a market capitalization of $3.63 billion and a PE ratio of 375.90.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. The business had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. The business’s quarterly revenue was up 113.0% compared to the same quarter last year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds have recently added to or reduced their stakes in the stock. Rossby Financial LCC acquired a new stake in Billiontoone during the fourth quarter worth approximately $25,000. Wells Fargo & Company MN acquired a new position in shares of Billiontoone in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone in the 4th quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone during the 4th quarter worth $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.